Latest fiscal year 2026 · computed deterministically from XBRL 10-K data · coverage 83%
In fiscal 2026, Vistagen Therapeutics, Inc. reported revenue of $1M, up 161.1% year over year. Operating margin was -5683.7% and net margin -5491.3%, on a free-cash-flow margin of n/a with capital expenditure at n/a of revenue. Every figure is computed directly from VTGN's SEC XBRL 10-K filing — deterministic, with no estimates.
| Fiscal year | Revenue | Op margin | Net margin |
|---|---|---|---|
| FY2026 | $1M | -5683.7% | -5491.3% |
| FY2025 | $0M | -11517.1% | -10579.8% |
| FY2024 | $1M | -3103.5% | -2759.6% |
| FY2023 | $-0M | 26109.3% | 26100.4% |
| FY2022 | $1M | -4308.3% | -4306.8% |
How does VTGN compare against its actual peer set?
A CompsDesk subscription covers unlimited benchmark packs on any covered company: up to 19 metrics (6 core guaranteed) × up to 5 fiscal years × up to 12 chosen peers, percentile placement, the subject's figures cited to their SEC tag, form and period with every company identified by its CIK, PDF-ready HTML + CSV, generated on demand.
Source: SEC EDGAR XBRL (10-K filings), latest filed values. "n/a" = not disclosed under mapped tags — never estimated. Informational benchmarking, not investment advice. © CompsDesk / Sam Arora.